QTRX

+ Watchlist + Portfolio

Quanterix Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.96
52-Week Range: $2.15 – $8.77
Market Cap: $147.55M
P/E (TTM): —
EPS (TTM): -2.62
Dividend Yield: —

Advanced Metrics

Price/Book: 0.62
PEG Ratio: —
Return on Equity: -46.48%
Return on Assets: -16.67%
Gross Margin: 44.56%
Operating Margin: -68.37%
Profit Margin: -80.25%
Current Ratio: 3.40
Debt/Equity: 0.14
Total Debt: $33.39M
Free Cash Flow: $-29.92M
Revenue Growth: 34.40%
Earnings Growth: —
Enterprise Value: $87.41M

QTRX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$104.95M	$121.14M	$135.44M	$138.65M
Cost of Revenue	$60.16M	$48.14M	$54.32M	$73.94M
Gross Profit	$44.79M	$73.00M	$81.12M	$64.72M
Research & Development	$26.81M	$26.06M	$31.08M	$35.92M
Selling, General & Admin	$93.26M	$92.82M	$104.64M	$138.85M
Operating Expenses	$119.50M	$117.66M	$133.74M	$174.53M
Operating Income	-$74.71M	-$44.66M	-$52.62M	-$109.81M
EBITDA	-$68.58M	-$36.37M	-$44.26M	-$90.89M
Pretax Income	-$99.41M	-$27.64M	-$38.10M	-$112.27M
Income Tax	$164.00K	$719.00K	$434.00K	-$5.12M
Net Income	-$99.57M	-$28.35M	-$38.53M	-$107.15M
Diluted EPS	-2.61	-0.75	-1.00	-2.51
Diluted Shares	36.99M	37.59M	38.37M	42.64M

QTRX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$338.74M	$174.42M	$56.71M	$29.84M
Receivables	$19.02M	$25.41M	$32.14M	$29.97M
Inventory	$16.96M	$26.12M	$32.77M	$54.76M
Current Assets	$381.52M	$382.10M	$363.59M	$212.26M
Total Assets	$433.58M	$428.57M	$406.53M	$418.77M
Current Liabilities	$31.35M	$38.98M	$42.01M	$74.76M
Total Debt	$44.10M	$41.46M	$37.37M	$37.24M
Total Liabilities	$75.65M	$78.61M	$76.50M	$123.04M
Retained Earnings	-$403.20M	-$431.55M	-$470.08M	-$577.23M
Shareholders' Equity	$357.93M	$349.96M	$330.04M	$295.73M
Working Capital	$350.18M	$343.11M	$321.59M	$137.50M

QTRX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$48.61M	-$18.85M	-$35.16M	-$77.24M
Capital Expenditure	-$11.61M	-$3.84M	-$3.37M	-$2.61M
Free Cash Flow	-$60.23M	-$22.69M	-$38.53M	-$79.85M
Depreciation & Amortisation	$6.12M	$8.29M	$8.36M	$18.93M
Stock-Based Compensation	$15.38M	$16.82M	$19.99M	$20.72M
Investing Cash Flow	-$11.09M	-$148.45M	-$82.27M	$50.23M
Financing Cash Flow	$2.31M	$2.69M	$456.00K	-$708.00K
Net Change in Cash	-$57.39M	-$164.61M	-$116.97M	-$27.71M

QTRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$30.33M	$24.45M	$40.15M	$43.78M	$36.41M
Cost of Revenue	$15.49M	$13.18M	$23.03M	$23.82M	$20.85M
Gross Profit	$14.84M	$11.28M	$17.12M	$19.96M	$15.57M
Research & Development	$10.04M	$9.08M	$8.01M	$8.80M	$7.32M
Selling, General & Admin	$31.17M	$31.65M	$39.35M	$35.11M	$29.77M
Operating Expenses	$41.20M	$40.71M	$47.27M	$43.83M	$37.09M
Operating Income	-$26.37M	-$29.43M	-$30.15M	-$23.87M	-$21.53M
EBITDA	-$24.18M	-$26.58M	-$25.57M	-$14.56M	-$15.92M
Pretax Income	-$23.42M	-$30.09M	-$36.00M	-$22.77M	-$17.55M
Income Tax	-$2.91M	-$73.00K	-$2.48M	$345.00K	-$7.00K
Net Income	-$20.50M	-$30.01M	-$33.52M	-$23.12M	-$17.54M
Diluted EPS	-0.53	-0.77	-0.73	-0.49	-0.37
Diluted Shares	38.72M	38.89M	46.06M	46.78M	46.98M

QTRX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$76.51M	$132.90M	$38.30M	$29.84M	$36.18M
Receivables	$28.26M	$23.55M	$33.03M	$29.97M	$26.78M
Inventory	$31.03M	$30.14M	$54.96M	$54.76M	$50.96M
Current Assets	$335.00M	$322.12M	$233.28M	$212.26M	$185.72M
Total Assets	$396.51M	$375.61M	$444.14M	$418.77M	$366.67M
Current Liabilities	$40.40M	$48.20M	$77.35M	$74.76M	$49.91M
Total Debt	$36.41M	$35.53M	$40.12M	$37.24M	$35.34M
Total Liabilities	$80.12M	$83.15M	$129.61M	$123.04M	$84.53M
Retained Earnings	-$490.58M	-$520.60M	-$554.12M	-$577.23M	-$594.77M
Shareholders' Equity	$316.39M	$292.46M	$314.53M	$295.73M	$282.14M
Working Capital	$294.61M	$273.92M	$155.93M	$137.50M	$135.82M

QTRX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$13.89M	-$5.66M	-$41.25M	-$16.44M	-$18.11M
Capital Expenditure	-$1.26M	-$777.00K	-$677.00K	—	-$87.00K
Free Cash Flow	-$15.14M	-$6.43M	-$41.93M	-$16.35M	-$18.19M
Depreciation & Amortisation	$2.19M	$2.85M	$4.58M	$9.31M	$5.60M
Stock-Based Compensation	$5.46M	$5.37M	$5.47M	$4.42M	$4.53M
Investing Cash Flow	$32.76M	$61.88M	-$52.85M	$8.44M	$25.26M
Financing Cash Flow	$93.00K	-$429.00K	$150.00K	-$522.00K	-$770.00K
Net Change in Cash	$18.97M	$55.80M	-$93.95M	-$8.53M	$6.39M

Market Snapshot

About

Quanterix has pioneered ultra-sensitive biomarker detection using its proprietary Simoa (Single Molecule Array) technology. The platform enables measurement of proteins at extremely low concentrations in blood, advancing early disease detection, drug development, and precision medicine. Quanterix serves pharmaceutical, clinical research, and diagnostic markets with instruments, consumables, and testing services.